arrow
F

Fei Zhou

China Jiliang University
H指数:37
被引数:3,737

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of rezvilutamide (Rez) plus androgen- deprivation therapy (ADT) in patients with high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) aged ≤64, 65-74, and ≥75 years: Post-hoc analysis of randomized phase III CHART trial

瑞维卢他胺(Rez)联合雄激素剥夺疗法(ADT)在高体积、转移性、激素敏感的前列腺癌(mHSPC)患者中的疗效和安全性(年龄≤64岁、65-74岁和≥75岁):随机III期CHART试验的事后分析

2024-12-010
PRE